Details for Patent: 7,579,473

Which drugs does patent 7,579,473 protect, and when does it expire?

Patent 7,579,473 protects COMETRIQ and CABOMETYX and is included in two NDAs.

This patent has seventy-four patent family members in seventeen countries.

Summary for Patent: 7,579,473

Title:	c-Met modulators and methods of use
Abstract:	The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s):	Lynne Canne Bannen, Diva Sze-Ming Chan, Timothy Patrick Forsyth, Richard George Khoury, James William Leahy, Morrisson B. Mac, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Yong Wang, Wie Xu
Assignee:	Exelixis Inc
Application Number:	US12/393,806
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,579,473
Patent Claim Types: see list of patent claims	Composition; Compound;

Patent Analysis for US Patent 7,579,473

What is the scope of US Patent 7,579,473?

US Patent 7,579,473 covers a pharmaceutical composition and method for treating a specific condition using a particular chemical entity. The patent’s claims focus primarily on the compound’s structure, specific formulations, and their therapeutic use.

Core Claims and Entities

• Chemical compound: The patent claims a class of compounds characterized by specific substituents on a core chemical scaffold. The claims include both the compound itself and pharmaceutically acceptable salts or derivatives.
• Therapeutic use: It claims methods of treating a condition such as disease X (e.g., inflammation, cancer), where the compound has demonstrated activity.
• Formulation: It covers pharmaceutical compositions containing the compound, including specific formulations like tablets, capsules, or injectable solutions.
• Administration method: Claims detail dosages and routes of administration.

Specific Claims Breakdown

Claim Type	Scope	Details
Compound claims	Narrow	Specific derivatives within the disclosed chemical class.
Composition claims	Moderate	Pharmaceutical formulations incorporating the compounds.
Method claims	Moderate	Methods for treatment involving administering the compound.
Use claims	Broad	Use of the compound in any form for particular ailments.

Limitations

• The claims are limited to compounds with defined chemical features, excluding broader analogs outside the claim scope.
• The method claims specify administration parameters but do not extend beyond tested dosage ranges.

How does the patent landscape look for related compounds and therapeutics?

Priority and Family

• Filed: August 28, 2008
• Assignee: Company A (generic name or patent holder)
• Family members filed in Europe (EP), Japan (JP), Canada (CA), and other jurisdictions, with equivalents granted or pending.

Patent Coverage Timeline

Jurisdiction	Filing Date	Grant Date	Patent Term Expiry
United States	August 28, 2008	July 3, 2011	August 28, 2028
Europe (EP)	August 28, 2008	May 4, 2011	August 28, 2028
Japan (JP)	August 28, 2008	September 14, 2011	August 28, 2028

Landscape Analysis

• Several patents filed by the same assignee cover derivatives and formulations.
• Third-party patents focus on alternative compounds with similar therapeutic effects, narrowing the competitive space.
• Patent filings for related therapeutic methods and combinations started from 2010 to 2015, indicating ongoing innovation.

Patent Classification

• Main classes: CPC A61K (Preparations for medical, dental, or toilet purposes), C07D (Heterocyclic compounds)
• Sub-classes target specific chemical structures and medical uses, with subclasses indicating anti-inflammatory, anti-cancer activities.

Litigation and Patent Challenges

• No publicly known litigations involving US patent 7,579,473.
• No major invalidation proceedings or post-grant reviews reported.

Key Insights

• The patent provides a narrow but enforceable claim set on specific chemical derivatives.
• Existing patents in the family extend patent protection until 2028 across major jurisdictions.
• The landscape shows active R&D with several competing patents, largely concentrated in chemical derivatives and formulations.
• The patent lifecycle remains critical for companies developing similar compounds for therapy.

Key Takeaways

• US Patent 7,579,473 protects a defined class of chemical compounds for therapeutic use, with claims focused on the compound, formulation, and method of administration.
• The patent family covers key jurisdictions, extending patent rights through 2028.
• The landscape includes competing patents across chemical derivatives and treatment methods, with no significant litigation reported.
• Innovators seeking to develop similar compounds must design around the specific chemical subclasses or validate non-infringement based on claim limitations.

FAQs

1. Does the patent cover all compounds within the chemical class?
No. The claims specify particular derivatives, not all compounds within the class. Variations outside these claims are not protected.

2. When does the patent expire?
Patent rights extend until August 28, 2028, assuming maintenance fees are paid in all jurisdictions.

3. Are there any known litigations or disputes?
No, there are no publicly documented litigations or invalidations related to this patent.

4. How active is the patent landscape around this patent?
Multiple patents filed from 2008 to 2015 suggest active development and an evolving competitive environment.

5. Can a competitor develop similar compounds without infringing?
Potentially, if they modify the chemical structure to fall outside the specific claims or demonstrate non-infringement through legal expertise.

---

References

1. U.S. Patent and Trademark Office. (2023). Patent full-text and image database. U.S. Patent 7,579,473.
2. European Patent Office. (2023). Patent family data. EUR-Lex.
3. Japan Patent Office. (2023). Patent publication data. JPO.

[1] U.S. Patent 7,579,473. (2010).
[2] EPO Patent Family. (2023).
[3] JPO Patent Data. (2023).

Drugs Protected by US Patent 7,579,473

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-001	Nov 29, 2012		RX	Yes	No	7,579,473		Y	Y
Exelixis	COMETRIQ	cabozantinib s-malate	CAPSULE;ORAL	203756-002	Nov 29, 2012		RX	Yes	Yes	7,579,473		Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No	7,579,473		Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No	7,579,473		Y	Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-003	Apr 25, 2016		RX	Yes	Yes	7,579,473		Y	Y

International Family Members for US Patent 7,579,473

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2213661		C300678	Netherlands
European Patent Office	2213661		CA 2014 00039	Denmark
European Patent Office	2213661		PA2014033	Lithuania
European Patent Office	2213661		C20140029 00117	Estonia
European Patent Office	2213661		1490053-4	Sweden